SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : 2014 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (306)4/28/2014 2:05:40 PM
From: tom pope  Read Replies (1) | Respond to of 487
 
Not a very exciting name, but -

EXEL

I went back in about 75 cents ago



To: scaram(o)uche who wrote (306)4/28/2014 5:46:11 PM
From: Ian@SI  Respond to of 487
 
EDIT: Oops, I see that this was already given.

This year you asked for picks without visible warts.

If not, I'd have submitted EXEL but I have difficulty getting over its starting a PhIII without first getting the FDA's blessing.



To: scaram(o)uche who wrote (306)4/29/2014 12:16:22 PM
From: tuck  Respond to of 487
 
I don't follow it closely, and it could still be viewed as expensive, but as far as I can tell, CLDX has had no major negative event.

Cheers, Tuck



To: scaram(o)uche who wrote (306)4/29/2014 2:22:33 PM
From: The Dodgy Ticker  Read Replies (1) | Respond to of 487
 
PPHM* is in several trials to validate Bavituximab as an immunological agent. It's cheap right now.

*Remember, Rick, you asked.
:-)


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News